Neumora Therapeutics (NMRA) Institutional Ownership $9.79 0.00 (0.00%) (As of 11:20 AM ET) Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Neumora Therapeutics (NASDAQ:NMRA)CurrentInstitutional OwnershipPercentage47.65%Number ofInstitutional Buyers(last 12 months)35TotalInstitutional Inflows(last 12 months)$86.27MNumber ofInstitutional Sellers(last 12 months)6TotalInstitutional Outflows(last 12 months)$14.37M Get NMRA Insider Trade Alerts Want to know when executives and insiders are buying or selling Neumora Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data NMRA Institutional Buying and Selling by Quarter Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Neumora Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/19/2024 Barclays PLC129,210$1.71M0.0%+352.9%0.080% 11/16/2024 Geode Capital Management LLC1,979,847$26.16M0.0%+54.0%1.225% 11/15/2024 Barclays PLC129,210$1.71M0.0%+352.9%0.080% 11/15/2024 Wexford Capital LP217,879$2.88M0.7%+90.1%0.135% 11/15/2024 State Street Corp1,790,707$23.66M0.0%+65.3%1.108% 11/15/2024 Quarry LP5,000$66K0.0%-50.0%0.003% Get the Latest News and Ratings for NMRA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Neumora Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/15/2024 Point72 Asset Management L.P.83,077$1.10M0.0%N/A0.051% 11/13/2024 FMR LLC7,749,156$102.37M0.0%-10.1%4.842% 11/13/2024 The Manufacturers Life Insurance Company 109,802$1.45M0.0%-1.8%0.069% 11/12/2024 Cerity Partners LLC242,900$3.21M0.0%N/A0.152% 11/12/2024 Charles Schwab Investment Management Inc.698,255$9.22M0.0%+139.7%0.436% 11/9/2024 Intech Investment Management LLC13,275$175K0.0%N/A0.008% 10/30/2024 Auour Investments LLC250,000$3.30M1.2%N/A0.156% 10/23/2024 Ballentine Partners LLC13,441$178K0.0%N/A0.008% 10/9/2024 Clarius Group LLC16,992$224K0.0%N/A0.011% 10/5/2024 Handelsbanken Fonder AB26,600$351K0.0%+35.0%0.017% 10/3/2024 SG Americas Securities LLC21,581$285K0.0%-62.5%0.014% 8/27/2024 Logos Global Management LP300,000$2.95M0.2%-21.5%0.188% 8/16/2024 Quarry LP10,000$98K0.0%N/A0.006% 8/15/2024 The Manufacturers Life Insurance Company111,828$1.10M0.0%+79.5%0.070% 8/14/2024 Marshall Wace LLP134,545$1.32M0.0%N/A0.084% 8/14/2024 Logos Global Management LP300,000$2.95M0.2%-21.5%0.188% 8/13/2024 Callan Capital LLC661,194$6.50M0.5%+222.6%0.414% 8/12/2024 SkyOak Wealth LLC15,000$147K0.0%N/A0.009% 8/12/2024 Amalgamated Bank2,910$29K0.0%+472.8%0.002% 8/3/2024 TD Asset Management Inc144,994$1.43M0.0%+31.6%0.091% 8/1/2024 Rhumbline Advisers103,258$1.02M0.0%+488.3%0.065% 7/29/2024 Principal Financial Group Inc.16,878$166K0.0%N/A0.011% 7/26/2024 Bank of New York Mellon Corp235,593$2.32M0.0%+474.1%0.148% 7/12/2024 SG Americas Securities LLC57,607$566K0.0%N/A0.036% 5/17/2024 Artal Group S.A.2,924,052$40.21M1.0%+14.5%1.833% 5/16/2024 Kennedy Capital Management LLC136,828$1.88M0.0%N/A0.086% 5/15/2024 Baker BROS. Advisors LP633,851$8.72M0.1%N/A0.397% 5/15/2024 Price T Rowe Associates Inc. MD752,924$10.35M0.0%N/A0.472% 5/14/2024 Nan Fung Group Holdings Ltd63,315$871K0.8%N/A0.040% 5/10/2024 Vanguard Group Inc.334,330$4.60M0.0%-12.2%0.210% 5/3/2024 Callan Capital LLC204,987$2.82M0.2%N/A0.129% 5/1/2024 Auour Investments LLC105,087$1.45M0.5%N/A0.066% 4/23/2024 Addis & Hill Inc314,821$4.19M3.6%N/A0.198% 4/22/2024 Windmill Hill Asset Management Ltd26,121$359K0.1%N/A0.016% Breaking News: Tesla headed to $500… (Ad)That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. 2/14/2024 Avidity Partners Management LP1,990,632$33.94M1.2%+10.6%1.304% 2/13/2024 Tower Research Capital LLC TRC2,558$44K0.0%N/A0.002% 2/6/2024 Amalgamated Bank1,709$29K0.0%N/A0.001% 2/1/2024 New York State Common Retirement Fund6,900$118K0.0%N/A0.005% 1/30/2024 Strs Ohio3,200$54K0.0%N/A0.002% 1/12/2024 SG Americas Securities LLC6,308$108K0.0%N/A0.004% 12/6/2023 Citigroup Inc.14,416$203K0.0%N/A0.009% 11/15/2023 Laurion Capital Management LP21,557$304K0.0%N/A0.014% 11/14/2023 Soros Fund Management LLC10,000$141K0.0%N/A0.007% 11/14/2023 Avidity Partners Management LP1,800,000$25.40M1.0%N/A1.179% 11/13/2023 FMR LLC5,624,353$79.36M0.0%N/A3.683% 11/9/2023 Johnson & Johnson912,128$12.87M4.7%N/A0.597% 10/23/2023 WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST3,309,124$46.69M0.6%N/A2.178% (Data available from 1/1/2016 forward) NMRA Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of NMRA shares? During the previous two years, 42 institutional investors and hedge funds held shares of Neumora Therapeutics. The most heavily invested institutionals were FMR LLC ($102.37M), WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST ($46.69M), Artal Group S.A. ($40.21M), Avidity Partners Management LP ($33.94M), Geode Capital Management LLC ($26.16M), State Street Corp ($23.66M), and Johnson & Johnson ($12.87M).Learn more on NMRA's institutional investors. What percentage of Neumora Therapeutics stock is owned by institutional investors? 47.65% of Neumora Therapeutics stock is owned by institutional investors. Learn more on NMRA's institutional investor holdings. Which institutional investors have been buying Neumora Therapeutics stock? Of the 40 institutional investors that purchased Neumora Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: FMR LLC ($5.62M), WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST ($3.31M), Avidity Partners Management LP ($1.99M), Johnson & Johnson ($912.13K), Price T Rowe Associates Inc. MD ($752.92K), State Street Corp ($707.41K), and Geode Capital Management LLC ($694.39K). How much institutional buying is happening at Neumora Therapeutics? Institutional investors have bought a total of 18,309,311 shares in the last 24 months. This purchase volume represents approximately $251.04M in transactions. Which Neumora Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Neumora Therapeutics stock in the last 24 months: FMR LLC ($873.31K), Logos Global Management LP ($164.69K), Vanguard Group Inc. ($46.62K), SG Americas Securities LLC ($36.03K), Quarry LP ($5K), and The Manufacturers Life Insurance Company ($2.03K). How much institutional selling is happening at Neumora Therapeutics? Institutional investors have sold a total of 1,127,678 shares in the last 24 months. This volume of shares sold represents approximately $14.37M in transactions. Related Companies Halozyme Therapeutics Institutional Ownership Krystal Biotech Institutional Ownership ADMA Biologics Institutional Ownership Arcellx Institutional Ownership CRISPR Therapeutics Institutional Ownership Immunovant Institutional Ownership ImmunityBio Institutional Ownership Denali Therapeutics Institutional Ownership Vericel Institutional Ownership Kymera Therapeutics Institutional Ownership This page (NASDAQ:NMRA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
